medicina57巻5号

2020年04月発行

特集 デキル内科医のコンサルト—専門医が教える隠れたエッセンス コンサルトを依頼する

特発性肺線維症を疑う場合

著者： 新津敬之¹ 上野清伸¹ 内田純二¹

所属機関： ¹大阪急性期・総合医療センター

ページ範囲：P.630 - P.634

Point
◎特発性肺線維症（IPF）は診断が遅れることや，専門施設への紹介の遅れによる死亡リスク上昇の可能性も指摘されており，早期診断が肝要である．
◎今後，抗線維化薬の適用範囲は広がる可能性がある．
◎早期診断，介入のためには両側肺底部の捻髪音（velcro crackles/fine crackles）に注目することが重要である．

参考文献

1）Travis MD, et al：An official American Thoracic Society/European Respiratory Society statement；Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188：733-748, 2013

2）Nathan SD, et al：Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 140：221-229, 2011

3）Vancheri C, et al：Idiopathic pulmonary fibrosis；A disease with similarities and links to cancer biology. Eur Respir J 35：496-504, 2010

4）Natsuizaka M, et al：Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 190：773-779, 2014.

5）Harari S, et al：Epidemiology of idiopathic pulmonary fibrosis；A population-based study in primary care. Intern Emerg Med, 2019［Epub ahead of print］

6）Guenther A, et al：The European IPF registry（eurIPFreg）；Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res 19：141, 2018

7）Mirjam JG, et al：Cough in idiopathic pulmonary fibrosis. European Respiratory Review 25：278-286, 2016

8）Suzuki A, et al：The clinical impact of major comorbidities on idiopathic pulmonary fibrosis. Respir Investig 55：94-103, 2017

9）García-Sancho C, et al：Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med 105：1902-1907, 2011

10）Cottin V, et al：Velcro crackles：the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 40：519-521, 2012

11）Sgalla G, et al：“Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease. BMC Pulm Med 18：103, 2018

12）Raghu G, et al：The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease；A prospective study. Chest 116：1168-1174, 1999

13）Raghu G, et al ：Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 198：44-68, 2018

14）Walsh SLF, et al：Diagnostic likelihood thresholds that define a working diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 200：1146-1153, 2019

15）American Thoracic Society：Idiopathic pulmonary fibrosis；Diagnosis and treatment. International consensus statement. American Thoracic Society（ATS）, and the European Respiratory Society（ERS）. Am J Respir Crit Care Med 161：646-664, 2000

16）Lamas DJ, et al：Delayed access and survival in idiopathic pulmonary fibrosis；A cohort study. Am J Respir Crit Care Med 184：842-847, 2011

17）Richeldi L, et al：Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis（PRAISE）；A phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med, 2019

18）Canestaro WJ, et al ：Drug treatment of idiopathic pulmonary fibrosis；Systematic review and network meta-Analysis. Chest 149：756-66, 2016

19）Noble PW, et al：Pirfenidone for idiopathic pulmonary fibrosis；Analysis of pooled data from three multinational phase 3 trials. Eur Respir J 47：243-53, 2016

20）Costabel U, et al：Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respir Res 20：55, 2019

21）Richeldi L, et al：Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370：2071-2082, 2019

22）Flaherty KR, et al ：Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381：1718-1727, 2019

23）Maher TM, et al：Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease；A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine, 2019